Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies - PubMed (original) (raw)
. 1988 Jun 1;140(11):3793-800.
Affiliations
- PMID: 3372993
Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies
C Lue et al. J Immunol. 1988.
Abstract
Ig class-, and IgA and IgG subclass-specific immune responses to a 23 valent pneumococcal polysaccharide vaccine were studied at a single-cell level in the peripheral blood of systemically immunized adults. With a solid phase enzyme-linked immunospot (ELISPOT) assay, PBMC from immunized individuals were assayed for spontaneous Ag-specific antibody (Ab) production before, and on days 7, 14, and 28 after vaccination. On the day of immunization, no spontaneous Ag-specific Ab-secreting cells could be detected. On day 7 after vaccination, a high frequency of cells secreting Ab specific for pneumococcal polysaccharides (PPS) was observed. The IgA class comprised 79% (geometric mean) of the Ag-specific Ab-secreting cells, whereas IgG- and IgM-secreting cells accounted for 12% and 9%, respectively. The majority of Ag-specific IgA-secreting cells produced Ab of the IgA2 isotype. Serum, saliva, and tears collected before and on days 7, 14, and 28 after vaccination were assayed for specific Ab to the vaccine (anti-PPS Ab) by an ELISA. Serum IgA anti-PPS Ab showed the highest increase after vaccination with a 19-fold increase (geometric mean) which peaked on day 14. However, the ratio of Ag-specific polymeric vs monomeric IgA did not change after immunization. Serum IgG and IgM anti-PPS Ab displayed mean increases of 5.5-fold and 5.6-fold, respectively, on day 14. The most pronounced increase of salivary anti-PPS Ab was observed in the IgG class (4.5-fold on day 28) followed by IgM (4-fold on day 28), IgA (2.0-fold on day 14), IgA1 (2.4-fold on day 14) and IgA2 (2.0-fold on day 14). The levels of total IgA, IgG, and IgM in saliva did not change significantly throughout the course of immunization. IgG and IgM anti-PPS Ab levels in tears increased less than in saliva, whereas IgA behaved similarly as in saliva. There were no significant differences in the Ag-specific increase rates between the IgA, IgG, and IgM isotypes in tears.
Similar articles
- Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses.
Tarkowski A, Lue C, Moldoveanu Z, Kiyono H, McGhee JR, Mestecky J. Tarkowski A, et al. J Immunol. 1990 May 15;144(10):3770-8. J Immunol. 1990. PMID: 2110213 - In vivo and in vitro humoral immunity in surgical patients: antibody response to pneumococcal polysaccharide.
Nohr CW, Latter DA, Meakins JL, Christou NV. Nohr CW, et al. Surgery. 1986 Aug;100(2):229-38. Surgery. 1986. PMID: 3488597 - [Correlation between IGA from colostrum and serum and IGA is closer than between salivary IGA and total IGA].
Tallería Orriols JJ, Blanco Quirós A, Gómez Carrasco JA, Díez Fernández T, Garrido M. Tallería Orriols JJ, et al. An Esp Pediatr. 1990 Jul;33(1):31-5. An Esp Pediatr. 1990. PMID: 2252283 Review. Spanish. - Induction and molecular properties of secretory and serum IgA antibodies specific for environmental antigens.
Mestecky J, Czerkinsky C, Russell MW, Brown TA, Prince SJ, Moldoveanu Z, Jackson S, Michalek SM, McGhee JR. Mestecky J, et al. Ann Allergy. 1987 Nov;59(5 Pt 2):54-9. Ann Allergy. 1987. PMID: 3318587 Review.
Cited by
- Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission.
Russell MW, Mestecky J. Russell MW, et al. Front Immunol. 2022 Aug 17;13:957107. doi: 10.3389/fimmu.2022.957107. eCollection 2022. Front Immunol. 2022. PMID: 36059541 Free PMC article. Review. - BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
Darwich A, Pozzi C, Fornasa G, Lizier M, Azzolini E, Spadoni I, Carli F, Voza A, Desai A, Ferrero C, Germagnoli L; ICH COVID-19 Task-force; Mantovani A, Rescigno M. Darwich A, et al. EMBO Mol Med. 2022 May 9;14(5):e15326. doi: 10.15252/emmm.202115326. Epub 2022 Apr 19. EMBO Mol Med. 2022. PMID: 35393790 Free PMC article. - Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV.
Reale M, Ucciferri C, Costantini E, Di Nicola M, Porreca A, Di Giovanni P, Pontolillo M, Auricchio A, Vecchiet J, Falasca K. Reale M, et al. Nutrients. 2021 Dec 9;13(12):4412. doi: 10.3390/nu13124412. Nutrients. 2021. PMID: 34959964 Free PMC article. - The Application of Single-Cell RNA Sequencing in Vaccinology.
Noé A, Cargill TN, Nielsen CM, Russell AJC, Barnes E. Noé A, et al. J Immunol Res. 2020 Aug 6;2020:8624963. doi: 10.1155/2020/8624963. eCollection 2020. J Immunol Res. 2020. PMID: 32802896 Free PMC article. Review. - Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives.
Wagner A, Weinberger B. Wagner A, et al. Front Immunol. 2020 Apr 23;11:717. doi: 10.3389/fimmu.2020.00717. eCollection 2020. Front Immunol. 2020. PMID: 32391017 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous